Health In Tech, Inc (HIT) Fair Value & Analysis
Technology · US · Market cap $70.8M
Fair value as of: Jun 26, 2026
Analysis
Health In Tech, Inc (HIT) currently trades at $0.9699, while our model-based Fair Value estimate is $0.3100 — implying the stock looks roughly 68.0% overvalued today. We read business quality at 91/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Health In Tech, Inc. operates as an insurance technology platform company in the United States. The company offers reference-based pricing, group insurance captives, community health plans, and association health programs for small businesses; SMR, a program manager specializing in customized self-funded benefits plans for businesses; ICE is, an MGU, which specializes in underwriting and providing administrative functions on behalf of stop loss carriers; and enhance do it yourself benefit system (eDIYBS), a web-based SaaS quoting platform to quote health insurance for small and medium sized employers. It also provides health intelligence (HI) cards to streamline the management of medical records and claims; and HI performance network, which offers a series of hospital facilities, as well as delivers medicare-based reimbursement pricing. Health In Tech, Inc. was founded in 2014 and is headquartered in Stuart, Florida.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Health In Tech, Inc (HIT) undervalued?
What is the fair value of HIT?
What is the quality score of HIT?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.